Suppression of gene expression by tethering KRAB domain to promoter of ER target genes

Journal of Steroid Biochemistry and Molecular Biology

Volumn 69, Issue 1-6, 1999, Pages 155-163

  Ma, Zhi Qing ^a   Tsai, Ming Jer ^a   Tsai, Sophia Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor target gene; Krupple associated box; Regulable repressor

Indexed keywords

ANTIESTROGEN; DNA; ESTROGEN; ESTROGEN RECEPTOR; MIFEPRISTONE; PROGESTERONE;

BREAST CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DNA BINDING; DNA RESPONSIVE ELEMENT; DOSE RESPONSE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; POLYMERASE CHAIN REACTION; REPRESSOR GENE;

BASE SEQUENCE; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; PROGESTERONE; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 0032976792     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00154-X     Document Type: Conference Paper

References (38)

1. D.W. Pfaff, S. Schwartz-Giblin, Cellular mechanisms of female reproductive behaviors, in: E. Knobil, J. D. Neil, L. L. Ewing, G. S. Greenwald, C. L. Market and D. W. Pfaff (Eds.), The Physiology of Reproduction, Vol. 2. Raven Press, New York, 1988, pp. 1487-1568.
2. Ciocca D.R., Roig L.M. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocrine Reviews. 16:1995;35-62.
3. Ferdrick J.L., Raafat A.M., Haslam S.Z. Mammary gland growth and development from the postnatal period to postmenopause: ovarian steroid receptor ontogeny and regulation in the mouse. Journal of Mammary Gland Biology and Neoplasia. 3:1998;7-22.
4. Russo I.H., Russo J. Role of hormones in mammary cancer initiation and progression. Journal of Mammary Gland Biology and Neoplasia. 3:1998;49-61.
5. Pike M.C., Krailo M.D., Herderson B.E., Casagrande J.T., Hoel D.G. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature. 303:1984;767-770.
6. Henderson B.E., Ross R., Berstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Research. 48:1988;246-253.
7. Kelsey J.L., Gammon M.D. The epidemiology of breast cancer. Ca: a Cancer Journal for Clinicians. 41:1991;146-165.
8. Lonning P.E., Lien E.A. Mechanisms of action of endocrine treatment in breast cancer. Critical Reviews in Oncology/Hematology. 21:1995;158-193.
9. O'Malley B.W. The steroid receptor superfamily: more excitement predicted for the future. Molecular Endocrinology. 4:1990;363-369.
10. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry. 63:1994;451-486.
11. Lippman M.E., Allegra J.C. Quantitive estrogen receptor analysis: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer. 46:1980;2829-2843.
12. Jordan V.C. Overview from an international conference on long-term tamoxifen therapy for breast cancer. Journal of National Cancer Institute. 84:1992;231-234.
13. Horwitz K. How do breast cancer become hormone resistant. Journal of Steroid Biochemistry and Molecular Biology. 49:1994;295-302.
14. Lemieux P., Fuqua S. The role of the estrogen receptor in tumor progression. Journal of Steroid Biochemistry and Molecular Biology. 56:1996;87-91.
15. Murphy L.C., Dotzlaw H., Leygue E., Douglas D., Coutts A., Watson P.H. Estrogen receptor variants and mutations. Journal of Steroid Biochemistry and Molecular Biology. 62:1997;363-372.
16. Power R.F., Mani S.K., Codina J., Conneely O.M., O'Malley B.W. Dopaminergic and ligand-independent activation of steriod receptors by a novel alternative pathway. Science. 254:1991;1636-1639.
17. Cho H., Katzenellenbogen B.S. Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Molecular Endocrinology. 7:1993;442-452.
18. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
19. Zwijsen R.M., Wientjens E., Klompmaker R., van der Sman J., Bernards R., Michalides R.J. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 88:1997;405-415.
20. Neuman E., Ladha M.H., Lin N., Upton T.M., Miller S.J., DiRenzo J., Pestell R.G., Hinds P.W., Dowdy S.F., Brown M., Ewen M.E. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Molecular and Cellular Biology. 17:1997;5338-5347.
21. Trowbridge J.M., Rogatsky I., Garabedian M.J. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proceedings of the National Academy of Sciences of the United States of America. 94:1997;10132-10137.
22. Wang Y., O'Malley B.W.J., Tsai S.Y., O'Malley B.W. A regulatory system for use in gene transfer. Proceedings of the National Academy of Sciences of the United States of America. 91:1994;8180-8184.
23. Wang Y., DeMayo F.J., Tsai S.Y., O'Malley B.W. Ligand-inducible and liver-specific target gene expression in transgenic mice. Nature Biotechnology. 15:1997;239-243.
24. Margolin J.F., Friedman J.R., Meyer W.K., Vissing H., Thiesen H.J., Rauscher F.J.R. Kruppel-associated boxes are potent transcriptional repression domains. Proceedings of the National Academy of Sciences of the United States of America. 91:1994;4509-4513.
25. Witzgall R., O'Leary E., Leaf A., Onaldi D., Bonventre J.V. The Kruppel-associated box-A (KRAB-A) domain of zinc finger proteins mediates transcriptional repression. Proceedings of the National Academy of Sciences of the United States of America. 91:1994;4514-4518.
26. Pengue G., Lania L. Kruppel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements. Proceedings of the National Academy of Sciences of the United States of America. 93:1996;1015-1020.
27. Vegeto E., Allan G.F., Schrader W.T., Tsai M.J., McDonnell D.P., O'Malley B.W. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell. 69:1992;703-713.
28. Vik D.P., Amiguet P., Moffat G.J., Fey M., Amiguet-Barras F., Wetsel R.A., Tack B.F. Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence. Biochemistry. 30:1991;1080-1085.
29. Witzgall R., O'Leary E., Gessner R., Ouellette A.J., Bonventre J.V. Kid-1, a putative renal transcription factor: regulation during ontogeny and in response to ischemia and toxic injury. Molecular and Cellular Biology. 13:1993;1933-1942.
30. Mader S., Chambon P., White J.H. Defining a minimal estrogen receptor DNA binding domain. Nucleic Acids Research. 21:1993;1125-1132.
31. Rusconi S., Yamamoto K.R. Functional dissection of the hormone and DNA binding activities of the glucocorticoid receptor. EMBO Journal. 6:1987;1309-1315.
32. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO Journal. 9:1990;2811-2818.
33. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B., Pike J.W., McDonnell D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Molecular Endocrinology. 8:1994;21-30.
34. Nawaz Z., Tsai M.J., McDonnell D.P., O'Malley B.W. Identification of novel steroid-response elements. Gene Expression. 2:1992;39-47.
35. Shibata H., Spencer T.E., Onate S.A., Jenster G., Tsai S.Y., Tsai M.-J., O'Malley B.W. Role of coactivators and corepressors in the mechanism of steroid/thyroid receptor action. Recent Progress in Hormone Research. 52:1997;141-165.
36. No D., Yao T.P., Evans R.M. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 93:1996;3346-3351.
37. Rivera V.M., Clackson T., Natesan S., Pollock R., Amara J.F., Keenan T., Magari S.R., Phillips T., Courage N.L., Cerasoli F. Jr., Holt D.A., Gilman M. A humanized system for pharmacologic control of gene expression. Nature Medicine. 2:1996;1028-1032. (see comments).
38. Brown A.M., Jeltsch J.M., Roberts M., Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proceedings of the National Academy of Sciences of the United States of America. 81:1984;6344-6348.